Cardiac Muscle Contraction

Category	Biology
Also known as	Heart Contraction, Cardiac Excitation-Contraction Coupling, Myocardial Contraction
Last updated	2026-04-14
Reading time	6 min read
Tags	cardiovascularcardiacmusclecalciumaction-potential

Overview

Cardiac muscle contraction is the fundamental mechanical process that propels blood through the circulatory system. Unlike skeletal muscle, which contracts only upon voluntary neural command, cardiac muscle generates its own rhythmic electrical impulses and contracts as a functional syncytium, with electrical signals propagating seamlessly from cell to cell through gap junctions. This automaticity ensures continuous, coordinated pumping throughout the organism's lifetime.

The heart beats approximately 100,000 times per day, requiring extraordinary metabolic endurance and precise regulation of contractile force. The molecular process underlying each heartbeat, known as excitation-contraction (E-C) coupling, converts an electrical impulse into mechanical force through a calcium-mediated signaling cascade that engages the same actin-myosin contractile machinery found in all muscle types, albeit with cardiac-specific regulatory mechanisms.

Figure: Cardiac excitation-contraction coupling via calcium-induced calcium release

How It Works

Cardiac contraction begins with an action potential generated by pacemaker cells in the sinoatrial (SA) node. These cells possess intrinsic automaticity due to the funny current (If), a mixed sodium-potassium current that produces slow spontaneous depolarization. When threshold is reached, the action potential propagates through atrial myocardium, the atrioventricular (AV) node (which introduces a critical delay), the bundle of His, Purkinje fibers, and finally ventricular myocardium.

In ventricular cardiomyocytes, the action potential triggers excitation-contraction coupling through calcium-induced calcium release (CICR). During the plateau phase of the cardiac action potential, L-type calcium channels (dihydropyridine receptors) in the sarcolemma open, allowing a small influx of extracellular calcium. This calcium binds to ryanodine receptors (RyR2) on the sarcoplasmic reticulum (SR), triggering the release of a much larger calcium store. The resulting surge in cytoplasmic calcium concentration (from ~100 nM to ~1 microM) drives contraction.

Calcium binds to troponin C on the thin filament, inducing a conformational change that moves tropomyosin and exposes myosin-binding sites on actin. Myosin heads undergo their power stroke cycle, pulling actin filaments toward the center of the sarcomere and generating force. The magnitude of force is proportional to cytoplasmic calcium concentration, following the Frank-Starling mechanism at the whole-organ level.

Relaxation requires active removal of calcium from the cytoplasm. SERCA2a (sarco/endoplasmic reticulum calcium ATPase) pumps approximately 70% of calcium back into the SR, while the sodium-calcium exchanger (NCX) extrudes the remaining 30% across the sarcolemma. Phospholamban regulates SERCA2a activity; when unphosphorylated, it inhibits SERCA2a, and when phosphorylated by PKA (in response to beta-adrenergic stimulation), it relieves this inhibition, enhancing relaxation rate (lusitropy).

Key Components

SA Node: The heart's primary pacemaker, generating 60-100 impulses per minute at rest.
L-type Calcium Channels: Voltage-gated channels responsible for the trigger calcium that initiates CICR. Target of calcium channel blocker drugs.
Ryanodine Receptors (RyR2): SR calcium release channels. Mutations cause catecholaminergic polymorphic ventricular tachycardia (CPVT).
Troponin Complex: Calcium-sensing regulatory complex on the thin filament. Cardiac troponins (cTnI, cTnT) are released into blood during myocardial injury and serve as the gold-standard biomarker for heart attack diagnosis.
SERCA2a: ATP-dependent calcium pump that refills the SR and drives relaxation. Reduced SERCA2a expression is a hallmark of heart failure.
Gap Junctions (Connexin-43): Intercellular channels that allow direct electrical coupling between cardiomyocytes, enabling synchronized contraction.

Peptide Connections

BNP (B-type natriuretic peptide) is released from ventricular cardiomyocytes in response to volume overload and wall stretch. While not directly involved in the contractile mechanism, BNP levels reflect the hemodynamic consequences of contractile dysfunction. Elevated BNP serves as both a diagnostic biomarker for heart failure and a therapeutic target; recombinant BNP (nesiritide) has been used to reduce preload in acute decompensated heart failure.
TB-500 (thymosin beta-4) has been investigated for its cardioprotective properties in preclinical models. Research has examined its potential to activate prosurvival signaling pathways in cardiomyocytes, promote coronary vessel development, and support cardiac repair processes following ischemic injury. Its role in actin dynamics may have implications for cardiomyocyte cytoskeletal integrity.
Natriuretic peptides (ANP from atria, BNP from ventricles, CNP from endothelium) collectively modulate cardiovascular hemodynamics through cGMP-mediated vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone system. These peptides provide critical feedback loops that adjust cardiac workload in response to volume and pressure changes.

Clinical Significance

Heart failure represents the clinical endpoint of contractile dysfunction, affecting over 60 million people worldwide. Systolic heart failure (HFrEF) involves reduced contractile force due to cardiomyocyte loss, impaired calcium handling, and sarcomeric dysfunction. SERCA2a downregulation and RyR2 calcium leak are molecular hallmarks that reduce both contractile strength and relaxation efficiency.

Arrhythmias arise from disruptions in the orderly propagation of electrical impulses. Abnormal automaticity, reentrant circuits, and triggered activity from calcium-handling defects can produce life-threatening ventricular tachycardia or fibrillation. Ischemic heart disease interrupts oxygen delivery to cardiomyocytes, causing ATP depletion, calcium overload, and irreversible contracture (rigor) if not resolved. Understanding E-C coupling at the molecular level is fundamental to developing therapies for these conditions.